EverHint – SMA 20/50 Crossover – Top 2 Buy and Top 5 Sell Signals for Sep 10, 2026
Excerpt: 7 signals (from 22 total). Healthcare leads (6). price range $8-$123.
What This Signal Is
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
Market Context
Broad equity markets are under modest selling pressure today, with all three major indices declining roughly 0.6% in tandem. This synchronized pullback suggests broad-based risk-off sentiment rather than sector-specific weakness, which is an important backdrop for moving average crossover signals like the SMA20/SMA50 strategy. When markets sell off uniformly, trend-following signals face a higher rate of false breakouts, as short-term momentum can quickly reverse and undercut recently established crossover levels.
The VIX jumping 8.38% to 17.84 is the most significant data point for signal quality today. While 17.84 remains below the 20 threshold typically associated with elevated fear, the sharp single-day spike indicates options markets are pricing in meaningfully wider intraday swings ahead. For SMA-based strategies, this elevated volatility can compress the signal-to-noise ratio — prices may oscillate around moving average levels without committing to a clean directional trend, increasing the likelihood of whipsaw entries and exits.
Healthcare emerging as the top sector for today's signals is notable given the risk-off tone. Healthcare tends to attract capital during periods of market uncertainty due to its defensive characteristics, making it a logical area where upward-sloping moving average structures can remain intact even as broader indices retreat. Traders should consider that while Healthcare signals may carry relatively stronger conviction in this environment, the broader market headwind and rising volatility warrant tighter risk management and potentially reduced position sizing across the full signal set.
🟢 Buy Signals (2 of 2 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | MCap |
|---|---|---|---|---|---|
| 1 | EXEL | Exelixis, Inc. | Healthcare | $57.43 | $14.4B |
| 2 | TGTX | TG Therapeutics, Inc. | Healthcare | $55.39 | $8.5B |
🔴 Sell Signals (5 of 20 total)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | MCap |
|---|---|---|---|---|---|
| 1 | AMRX | Amneal Pharmaceuticals... | Healthcare | $16.87 | $5.4B |
| 2 | ASB | Associated Banc-Corp | Financial Services | $30.34 | $5.7B |
| 3 | ATR | AptarGroup, Inc. | Healthcare | $123.05 | $7.9B |
| 4 | BCRX | BioCryst Pharmaceutica... | Healthcare | $8.29 | $2.1B |
| 5 | BJ | BJ's Wholesale Club Ho... | Consumer Defensive | $89.65 | $11.4B |
Field Notes
Sector concentration: Healthcare (6), Financial Services (6), Industrials (4)
Data coverage: 0.0% insider (7d), 0.0% congressional (30d), 0.0% earnings, 27.3% news (7d)
Peer Analysis
BJ (BJ's Wholesale Club Holdings, Inc.): Leads 5 peers: HRL ($20.84), COKE ($188.80), BF-B ($26.59), CLX ($88.77), ACI ($11.69)
Recent Headlines
ATR (AptarGroup, Inc.)
- AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
BJ (BJ's Wholesale Club Holdings, Inc.)
- BJ's Wholesale Club Holdings 2026 Outlook: Aggressive Expansion Targets 12 New Warehouse Clubs
- Amundi Purchases 270,253 Shares of BJ’s Wholesale Club Holdings, Inc. $BJ
TGTX (TG Therapeutics, Inc.)
- TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Vlad's Take
Today's signals: Strong sector concentration in Healthcare (6 signals) suggests sector-specific rotation.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.